SCHEMBL951029

SCHEMBL951029

CN(C)Cc1ncc2n1C(=O)N(C1CCNCC1)C2

nearest known ligand 0.37

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
F10 P00742 5/20 0.37
F2 P00734 3/20 0.37
PLAT P00750 1/20 0.36
TP53 P04637 1/20 0.32
ITGB3 P05106 1/20 0.31
ITGA2B P08514 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL949948 0.88 F10 (0.36) F10F2PLAT
SCHEMBL950618 0.83 F10 (0.35) F10F2PLATTP53
SCHEMBL950873 0.81 F10 (0.35) F10F2ITGB3ITGA2B
SCHEMBL949125 0.79 F10 (0.43) F10F2TP53
SCHEMBL947564 0.78 CHRM2 (0.45) F10F2
Hydrochloric Acid SCHEMBL947909 0.78 F10 (0.43) F10F2TP53
SCHEMBL947603 0.78 F10 (0.33) F10F2
Hydrochloric Acid SCHEMBL947935 0.74 F10 (0.38) F10F2
Hydrochloric Acid SCHEMBL3448545 0.71 F10 (0.39) F10F2
SCHEMBL6219253 0.70 F10 (0.36) F10F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-13 US disclosed
US-20070004736-A1 Imidazole derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-04 US disclosed
EP-1564213-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004736-A1 Imidazole derivative, process for producing the same, and use HRH4, F2, HRH2 F10 545/4885F2 2/4885PLAT 462/4885
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE F2, H1-3, CYC1 F10 490/4885F2 1/4885PLAT 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.